CDK 4/6 Inhibitors: Evolution and Revolution in the Management of ER+ Metastatic Breast Cancer-Reference-Cited by-同舟云学术

CDK 4/6 Inhibitors: Evolution and Revolution in the Management of ER+ Metastatic Breast Cancer

Published:2021-10-12 Issue: Volume: Page:
ISSN:2688-1527
Container-title:JCO Oncology Practice
language:en
Short-container-title:JCO Oncology Practice

Author:

Reddy Priyanka M.¹,Martin James M.¹^ORCID,Montero Alberto J.¹^ORCID

Affiliation:

1. Division of Hematology and Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Oncology(nursing),Health Policy,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/OP.21.00611

Reference8 articles.

1. Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3.

2. Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).

3. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cyclin dependent kinase 9 inhibition reduced programmed death-ligand 1 expression and improved treatment efficacy in hepatocellular carcinoma;Heliyon;2024-07

2. First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting;Breast Cancer Research and Treatment;2024-06-26

3. ER/PR‐Positive, HER2‐Negative Metastatic Breast Cancer;Cancer Consult;2023-11-13

4. Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression;Frontiers in Oncology;2023-10-04

5. Patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a real-world study in Italy;Breast Cancer Management;2023-06-01